Activation of mucosal immunity as a novel therapeutic strategy for combating brucellosis
- PMID: 36620020
- PMCID: PMC9814167
- DOI: 10.3389/fmicb.2022.1018165
Activation of mucosal immunity as a novel therapeutic strategy for combating brucellosis
Abstract
Brucellosis is a disease of livestock that is commonly asymptomatic until an abortion occurs. Disease in humans results from contact of infected livestock or consumption of contaminated milk or meat. Brucella zoonosis is primarily caused by one of three species that infect livestock, Bacillus abortus in cattle, B. melitensis in goats and sheep, and B. suis in pigs. To aid in disease prophylaxis, livestock vaccines are available, but are only 70% effective; hence, improved vaccines are needed to mitigate disease, particularly in countries where disease remains pervasive. The absence of knowing which proteins confer complete protection limits development of subunit vaccines. Instead, efforts are focused on developing new and improved live, attenuated Brucella vaccines, since these mimic attributes of wild-type Brucella, and stimulate host immune, particularly T helper 1-type responses, required for protection. In considering their development, the new mutants must address Brucella's defense mechanisms normally active to circumvent host immune detection. Vaccination approaches should also consider mode and route of delivery since disease transmission among livestock and humans is believed to occur via the naso-oropharyngeal tissues. By arming the host's mucosal immune defenses with resident memory T cells (TRMs) and by expanding the sources of IFN-γ, brucellae dissemination from the site of infection to systemic tissues can be prevented. In this review, points of discussion focus on understanding the various immune mechanisms involved in disease progression and which immune players are important in fighting disease.
Keywords: Brucella; CD8+ T cells; cell-mediated immunity; mucosal immunity; pathogenesis; resident memory T cells; vaccination.
Copyright © 2022 Pascual, Goodwin, Bhagyaraj, Hoffman and Yang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Protective live oral brucellosis vaccines stimulate Th1 and th17 cell responses.Infect Immun. 2011 Oct;79(10):4165-74. doi: 10.1128/IAI.05080-11. Epub 2011 Jul 18. Infect Immun. 2011. PMID: 21768283 Free PMC article.
-
Live mucosal vaccination stimulates potent protection via varied CD4+ and CD8+ T cell subsets against wild-type Brucella melitensis 16M challenge.Front Immunol. 2022 Oct 3;13:995327. doi: 10.3389/fimmu.2022.995327. eCollection 2022. Front Immunol. 2022. PMID: 36263034 Free PMC article.
-
Recent developments in livestock and wildlife brucellosis vaccination.Rev Sci Tech. 2013 Apr;32(1):207-17. doi: 10.20506/rst.32.1.2201. Rev Sci Tech. 2013. PMID: 23837378 Review.
-
Targeting resident memory T cell immunity culminates in pulmonary and systemic protection against Brucella infection.PLoS Pathog. 2020 Jan 17;16(1):e1008176. doi: 10.1371/journal.ppat.1008176. eCollection 2020 Jan. PLoS Pathog. 2020. PMID: 31951645 Free PMC article.
-
Brucellosis vaccines for livestock.Vet Immunol Immunopathol. 2016 Nov 15;181:51-58. doi: 10.1016/j.vetimm.2016.03.011. Epub 2016 Mar 16. Vet Immunol Immunopathol. 2016. PMID: 27032465 Review.
Cited by
-
Interactions between B cells and T follicular regulatory cells enhance susceptibility to Brucella infection independent of the anti-Brucella humoral response.PLoS Pathog. 2023 Sep 18;19(9):e1011672. doi: 10.1371/journal.ppat.1011672. eCollection 2023 Sep. PLoS Pathog. 2023. PMID: 37721965 Free PMC article.
-
Contrasting roles for IgM and B-cell MHCII expression in Brucella abortus S19 vaccine-mediated efficacy against B. melitensis infection.mSphere. 2024 Mar 26;9(3):e0075023. doi: 10.1128/msphere.00750-23. Epub 2024 Feb 13. mSphere. 2024. PMID: 38349167 Free PMC article.
-
Design of an oral vaccine using Lactococcus lactis against brucellosis: an in vitro and in vivo study.AMB Express. 2024 Jan 3;14(1):2. doi: 10.1186/s13568-023-01638-4. AMB Express. 2024. PMID: 38170414 Free PMC article.
-
A Single Nasal Dose Vaccination with a Brucella abortus Mutant Potently Protects against Pulmonary Infection.J Immunol. 2023 May 15;210(10):1576-1588. doi: 10.4049/jimmunol.2300071. J Immunol. 2023. PMID: 37036290 Free PMC article.
-
Parenteral Vaccination with a Live Brucella melitensis Mutant Protects against Wild-Type B. melitensis 16M Challenge.Microorganisms. 2024 Jan 15;12(1):169. doi: 10.3390/microorganisms12010169. Microorganisms. 2024. PMID: 38257995 Free PMC article.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials